Jacobs Levy Equity Management’s NanoViricides NNVC Stock Holding History

Jacobs Levy Equity Management’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-835	Closed	-$50K	–	879
2014 Q3	$50K	Buy	835 +65	+8%	+$5.11K	﹤0.01%	803
2014 Q2	$65K	Buy	+770	New	+$54.7K	﹤0.01%	813

Other funds holding NNVC

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Jacobs Levy Equity Management's NNVC Position: Q4 2014 in Review

Jacobs Levy Equity Management sold out of NanoViricides (NNVC) in Q4 2014, closing a stake of 835 shares — an estimated $50K sold.

Jacobs Levy Equity Management first reported a position in NNVC in Q2 2014 and held it in 2 quarters. The position peaked at $65K in Q2 2014. 54 funds tracked by Wall St. Rank hold NNVC as of Q4 2014.

Jacobs Levy Equity Management reported no remaining NanoViricides position as of Q4 2014 after selling out during the quarter.
Jacobs Levy Equity Management sold 835 NanoViricides shares in Q4 2014, an estimated $50K.
Jacobs Levy Equity Management first reported a position in NanoViricides in Q2 2014 and held it in 2 quarters.
Jacobs Levy Equity Management's NanoViricides position peaked at $65K in Q2 2014.
54 funds tracked by Wall St. Rank held NanoViricides as of Q4 2014.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2014, filed 17 Feb 2015.